NFE2L2 and neurodegenerative disease: Thus, while more in vitro and in vivo evidence of a role for NRF2 in preserving the NSC pool in neurodegenerative disease is needed, these studies clearly indicate that loss of NRF2 is detrimental during age-related pathogenesis, and that NRF2 activators could be of therapeutic benefit for this subset of diseases, partly by promoting NSC survival.